Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Staels: Therapeutic roles of peroxisome proliferator–activated receptor agonists. (0.11 sec) 

Therapeutic roles of peroxisome proliferator–activated receptor agonists

- shouxi.net
B Staels, JC Fruchart - Diabetes, 2005 - Am Diabetes Assoc
Peroxisome proliferator–activated receptors (PPARs) play key roles in the
regulation of energy homeostasis and inflammation, and agonists of PPARα and
-γ are currently used therapeutically. Fibrates, first used in the 1970s ...
Cited by 265 - Related articles - BL Direct - All 10 versions

Molecular characterization of new selective peroxisome proliferator–activated receptor γ …

- shouxi.net
M Schupp, M Clemenz, R Gineste, H Witt, J … - Diabetes, 2005 - Am Diabetes Assoc
Selective peroxisome proliferator–activated receptor (PPAR) γ modulation is a
new pharmacological approach that, based on selective receptor-cofactor
interactions and target gene regulation, should result in potent insulin ...
Cited by 141 - Related articles - BL Direct - All 6 versions

PPARs: therapeutic targets for metabolic disease

- cell.com
JP Berger, TE Akiyama, PT Meinke - Trends in Pharmacological Sciences, 2005 - Elsevier
The three peroxisome-proliferator-activated receptor (PPAR) subtypes, PPAR-γ,
PPAR-α and PPAR-δ, are nuclear receptors that have been the focus of extensive
research during the past decade. These receptors function as lipid sensors ...
Cited by 242 - Related articles - All 6 versions

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type …

- jhsph.edu [PDF] 
SE Nissen, K Wolski, EJ Topol - Jama, 2005 - Am Med Assoc
Context Peroxisome proliferator–activated receptors (PPARs) are nuclear
transcription factors that modulate gene expression. Therapeutic agents
targeting 2 distinct families of PPARs ( and ) have been introduced in the ...
Cited by 259 - Related articles - BL Direct - All 9 versions

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with …

- scfmresidency.com [PDF]  - Free from Publisher
RB Goldberg, DM Kendall, MA Deeg, JB Buse, … - Diabetes care, 2005 - Am Diabetes Assoc
RESEARCH DESIGN AND METHODS—We enrolled subjects with a diagnosis of type 2
diabetes (treated with diet alone or oral monotherapy) and dyslipidemia (not
treated with any lipid-lowering agents). After a 4-week placebo washout ...
Cited by 335 - Related articles - BL Direct - All 13 versions

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression …

- ahajournals.org
N Marx, H Duez, JC Fruchart, B Staels - Circulation Research, 2004 - Am Heart Assoc
A large body of data gathered over the past couple of years has identified the
peroxisome proliferator-activated receptors (PPAR) , , and ß/ as transcription
factors exerting modulatory actions in vascular cells. PPARs, which belong ...
Cited by 333 - Related articles - BL Direct - All 7 versions

Sorting out the roles of PPARα in energy metabolism and vascular homeostasis

- nih.gov
P Lefebvre, G Chinetti, JC Fruchart, B Staels - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig
PPARα is a nuclear receptor that regulates liver and skeletal muscle lipid
metabolism as well as glucose homeostasis. Acting as a molecular sensor of
endogenous fatty acids (FAs) and their derivatives, this ligand-activated ...
Cited by 206 - Related articles - BL Direct - All 9 versions

Dual and pan-peroxisome proliferator-activated receptors(PPAR) co-agonism: the …


A Tenenbaum, M Motro, EZ Fisman - Cardiovascular Diabetology, 2005 - biomedcentral.com
There are three peroxisome proliferator-activated receptors (PPARs) subtypes
which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR
alpha activation increases high density lipoprotein (HDL) cholesterol ...
Cited by 94 - Related articles - Cached - All 13 versions

Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, …


JB Buse, CJ Rubin, R Frederich, K Viraswami … - Clinical therapeutics, 2005 - Elsevier
This was a randomized, double-blind, placebo-controlled, parallel-group,
multicenter, 24-week monotherapy study in drug-naive, type 2 diabetes patients
with inadequate glycemic control. Men and women aged 18 to 70 years with a ...
Cited by 65 - Related articles - All 6 versions

Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes


F Blaschke, Y Takata, E Caglayan, RE Law, … - Arteriosclerosis, thrombosis, and vascular biology, 2006 - Am Heart Assoc
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated
transcription factors belonging to the nuclear hormone receptor superfamily. The
3 PPAR isotypes, PPAR- , PPAR- , and PPAR- , play a key role in the ...
Cited by 73 - Related articles - All 10 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google